StockData

Insmed vs Legend Biotech

INSM and LEGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INSM and LEGN compare

Insmed grew revenue faster over the last twelve months (240% versus 59.5% for Legend Biotech).

Insmed scores higher on the StockData Score (8 against 3 for Legend Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINSMLEGN
Size and price
Market cap$26.7B–
Share price$121.86$16.11
Change, 1 year−36.9%−46.8%
Change, 5 years321%−70.2%
Beta (5Y)0.840.80
Employees1,6642,900
StockData Score
Total score8 (better)3
Valuation score00
Growth score3 (better)2
Performance score2 (better)0
Health score3 (better)1
Dividend score00
Valuation
P/S17.6×–
P/B36.8×–
FCF yield−2.3%–
Fair value$61.10–
Margin of safety−99.5%–
Growth
Revenue growth (TTM)240% (better)59.5%
Revenue growth, 5Y average29.8%68.8% (better)
Profitability
Gross margin84.4% (better)57.2%
Operating margin−37.1%−4.3% (better)
Net margin−39.9%–
FCF margin−41.3%−9.6% (better)
Return on equity−72.5%–
Financial health
Debt / equity0.76–
Interest coverage−6.9×−2.5× (better)
Current ratio2.863.04 (better)
Altman Z-score7.42–
Piotroski F-score4–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions102%28.4%
Held by insiders0.89%0.50%
Insider net buying, 12 months−$133M−$384K (better)
Superinvestors holding11
Short interest, % of float6.5%–

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.